Prostate Cancer and Race

Current Problems in Cancer

Volumn 31, Issue 3, 2007, Pages 211-225

  Brawley, Otis W ^a   Jani, Ashesh B ^a   Master, Veraj ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; HUMAN; OUTCOMES RESEARCH; PROSTATE CANCER; RACE DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 34249704476     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2007.01.006     Document Type: Article

References (74)

1. Potosky A.L., Feuer E.J., and Levin D.L. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 23 (2001) 181-186
2. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2002.
3. Shibata A., Ma J., and Whittemore A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90 (1998) 1230-1231
4. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring. J Natl Cancer Inst 97 (2005) 1407-1427
5. Kramer B.S., Brown M.L., Prorok P.C., Potosky A.L., and Gohagan J.K. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119 (1993) 914-923
6. Boyle P. Screening for prostate cancer: have you had your cholesterol measured?. BJU Int 92 (2003) 191-199
7. Miller D.C., Gruber S.B., Hollenbeck B.K., Montie J.E., and Wei J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98 (2006) 1134-1141
8. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
9. Lu-Yao G., Albertsen P.C., Stanford J.L., Stukel T.A., Walker-Corkery E.S., and Barry M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 325 (2002) 740
10. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
11. Shibata A., Ma J., and Whittemore A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90 (1998) 1230-1231
12. Yao S.L., and Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 94 (2002) 958-960
13. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La P.G., Haile R.W., et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89 (1997) 166-170
14. Liu L., Cozen W., Bernstein L., Ross R.K., and Deapen D. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst 93 (2001) 705-709
15. Steenland K., Rodriguez C., Mondul A., Calle E.E., and Thun M. Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control 15 (2004) 939-945
16. Bennett C.L., Ferreira M.R., Davis T.C., Kaplan J., Weinberger M., Kuzel T., et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 16 (1998) 3101-3104
17. Roetzheim R.G., Pal N., Tennant C., Voti L., Ayanian J.Z., Schwabe A., et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst 91 (1999) 1409-1415
18. Polednak A.P. Stage at diagnosis of prostate cancer in Connecticut by poverty and race. Ethn Dis 7 (1997) 215-220
19. Schwartz K.L., Crossley-May H., Vigneau F.D., Brown K., and Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 14 (2003) 761-766
20. Pan C.C., Lee J.S., Chan J.L., Sandler H.M., Underwood W., and McLaughlin P.W. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates. Int J Radiat Oncol Biol Phys 57 (2003) 1292-1296
21. Brown M.L., and Potosky A.L. The presidential effect: the public health response to media coverage about Ronald Reagan's colon cancer episode. Public Opin Q 54 (1990) 317-329
22. Satia-Abouta J., Patterson R.E., Schiller R.N., and Kristal A.R. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med 34 (2002) 493-501
23. Tarman G.J., Kane C.J., Moul J.W., Thrasher J.B., Foley J.P., Wilhite D., et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology 56 (2000) 1016-1020
24. Gordon N.H. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142 (1995) 796-803
25. Harlan L.C., Coates R.J., Block G., Greenberg R.S., Ershow A., Forman M., et al. Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology 4 (1993) 25-31
26. Brewster D.H., Thomson C.S., Hole D.J., Black R.J., Stroner P.L., and Gillis C.R. Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. Br Med J 322 (2001) 830-831
27. Amling C.L., Riffenburgh R.H., Sun L., Moul J.W., Lance R.S., Kusuda L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
28. Amling C.L., Kane C.J., Riffenburgh R.H., Ward J.F., Roberts J.L., Lance R.S., et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58 (2001) 723-728
29. Sakr W.A., Grignon D.J., Crissman J.D., Heilbrun L.K., Cassin B.J., Pontes J.J., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
30. Sakr W.A., Billis A., Ekman P., Wilt T., and Bostwick D.G. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol Suppl (2000) 11-18
31. Soos G., Tsakiris I., Szanto J., Turzo C., Haas P.G., and Dezso B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol 48 (2005) 739-744
32. Sanchez-Chapado M., Olmedilla G., Cabeza M., Donat E., and Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 54 (2003) 238-247
33. Haenszel W., and Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40 (1968) 43-68
34. Haenszel W. Studies of migrant populations. Am J Public Health 75 (1985) 225-226
35. Ross R.K., Pike M.C., Coetzee G.A., Reichardt J.K., Yu M.C., Feigelson H., et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58 (1998) 4497-4504
36. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
37. Brawley O.W., Ford L.G., Thompson I., et al. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 3 (1994) 177-182
38. Ross R.K. The role of molecular genetics in chemoprevention studies of prostate cancer. IARC Sci Publ 154 (2001) 207-213
39. Salam M.T., Ursin G., Skinner E.C., Dessissa T., and Reichardt J.K. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 23 (2005) 246-253
40. Kidd L.C., Paltoo D.N., Wang S., Chen W., Akereyeni F., Isaacs W., et al. Sequence variation within the 5′ regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate 64 (2005) 272-282
41. Thompson I.M., Basler J.A., Leach R., Troyer D., Klein E., and Brawley O. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer. Urol Oncol 21 (2003) 73-78
42. Irvine R.A., Yu M.C., Ross R.K., and Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55 (1995) 1937-1940
43. Platz E.A., Rimm E.B., Willett W.C., Kantoff P.W., and Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 92 (2000) 2009-2017
44. Kittles R.A., Young D., Weinrich S., Hudson J., Argyropoulos G., Ukoli F., et al. Extent of linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. Hum Genet 109 (2001) 253-261
45. Sartor O., Zheng Q., and Eastham J.A. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 53 (1999) 378-380
46. Panz V.R., Joffe B.I., Spitz I., Lindenberg T., Farkas A., and Haffejee M. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine 15 (2001) 213-216
47. Bennett C.L., Price D.K., Kim S., Liu D., Jovanovic B.D., Nathan D., et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol 20 (2002) 3599-3604
48. Powell I.J., Land S.J., Dey J., Heilbrun L.K., Hughes M.R., Sakr W., et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 103 (2005) 528-537
49. Morris C.R., Snipes K.P., Schlag R., and Wright W.E. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control 10 (1999) 503-511
50. Kane C.J., Lubeck D.P., Knight S.J., Spitalny M., Downs T.M., Grossfeld G.D., et al. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology 62 (2003) 1035-1039
51. Harlan L., Brawley O., Pommerenke F., Wali P., and Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 13 (1995) 93-100
52. Klabunde C.N., Potosky A.L., Harlan L.C., and Kramer B.S. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 36 (1998) 1337-1348
53. Harlan L.C., Potosky A., Gilliland F.D., Hoffman R., Albertsen P.C., Hamilton A.S., et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93 (2001) 1864-1871
54. Shavers V.L., Brown M.L., Potosky A.L., Klabunde C.N., Davis W.W., Moul J.W., et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 19 (2004) 146-155
55. Shavers V.L., Brown M., Klabunde C.N., Potosky A.L., Davis W., Moul J., et al. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Med Care 42 (2004) 239-250
56. Oakley-Girvan I., Kolonel L.N., Gallagher R.P., Wu A.H., Felberg A., and Whittemore A.S. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health 93 (2003) 1753-1759
57. Godley P.A., Schenck A.P., Amamoo M.A., Schoenbach V.J., Peacock S., Manning M., et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 95 (2003) 1702-1710
58. Robbins A.S., Whittemore A.S., and Thom D.H. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol 151 (2000) 409-416
59. Bach P.B., Schrag D., Brawley O.W., Galaznik A., Yakren S., and Begg C.B. Survival of blacks and whites after a cancer diagnosis. J Am Med Assoc 287 (2002) 2106-2113
60. Shavers V.L., and Brown M.L. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94 (2002) 334-357
61. Young C.D., Lewis P., Weinberg V., Lee T.T., Coleman C.W., and Roach III M. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy. Semin Urol Oncol 18 (2000) 121-126
62. Hart K.B., Wood Jr. D.P., Tekyi-Mensah S., Porter A.T., Pontes J.E., and Forman J.D. The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy. Int J Radiat Oncol Biol Phys 45 (1999) 1235-1238
63. Roach III M., Krall J., Keller J.W., Perez C.A., Sause W.T., Doggett R.L., et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys 24 (1992) 441-449
64. Freedland S.J., Jalkut M., Dorey F., Sutter M.E., and Aronson W.J. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology 56 (2000) 87-91
65. Fowler Jr. J.E., Terrell F.L., and Renfroe D.L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 156 (1996) 1714-1718
66. Iselin C.E., Box J.W., Vollmer R.T., Layfield L.J., Robertson J.E., and Paulson D.F. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 83 (1998) 2353-2360
67. McLeod D.G., Schellhammer P.F., Vogelzang N.J., Soloway M.S., Sharifi R., Block N.L., et al., The Casodex Combination Study Group. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. Prostate 40 (1999) 218-224
68. Fowler J.E., Bigler S.A., Renfroe D.L., and Dabagia M.D. Prostate specific antigen in black and white men after. J Urol 158 (1997) 150-154
69. Tannock I.F., de W.R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
70. Austin J.P., Aziz H., Potters L., Thelmo W., Chen P., Choi K., et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol 13 (1990) 465-469
71. Kim J.A., Kuban D.A., el-Mahdi A.M., and Schellhammer P.F. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology 194 (1995) 545-549
72. Austin J.P., and Convery K. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation. Am J Clin Oncol 16 (1993) 140-145
73. Johnstone P.A., Kane C.J., Sun L., Wu H., Moul J.W., McLeod D.G., et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology 225 (2002) 420-426
74. Brawley O.W. Population categorization and cancer statistics. Cancer Metastasis Rev 22 (2003) 11-19